Delivery order 75N91020F00003UNIVERSITY OF OKLAHOMA
Overview
Award facts
- Net obligations
- $780.91K
- $780,910of $780.91K potential value
- Outlays (paid to date)
- $521.17K
- $521.17K paid of $780.91K obligated$521,169
- Period of performance
- Sep 21, 2020 to Jun 20, 2025
- Ended
- Modifications
- 5
- Latest action May 5, 2025
- Contract type
- Delivery order
- PIID 75N91020F00003
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN)WHEN ADMINISTERED IN COMBINATION.
Dates and value
- Award date
- Signed on Sep 9, 2020
- Potential end of performance
- Jun 19, 2025
- Current value
- $780,910Base and exercised options
- Potential value (if all options are exercised)
- $780,910
- Parent contract vehicle
- 75N91019D00020 (IDC, multiple award) — 15 orders recorded under it
Obligations by fiscal year of action
- FY2025: -$4,250 (de-obligation)
- FY2020: $785,160
Total across 2 fiscal years: $780,910
Net de-obligation in that fiscal year (obligations withdrawn).
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded May 5, 2025. View on USAspending · Recipient on SAM.gov
Recipient
Business types and certifications
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NIH NCI
- Funded from
- National cancer institute (0849)Program activities075-0849Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Oklahoma City, Oklahoma County, Oklahoma 73104-3609
- Congressional district (place of performance)
- OK-05As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Subject to multiple award fair opportunityMAFO
- Set-aside
- No set-aside used
- Contract pricing
- Firm fixed priceJ
- Offers received
- 1
Solicitation and notices
- Solicitation ID
- TORFP 2020-E07(as reported)
- Solicitation date
- May 4, 2020
Contract details
- Subcontracting plan
- Individual subcontract planF
- Major program
- Prevent efficacy pool: prevent cancer preclinical durg development program
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- Yes - service where PBA is used.Y
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 9, 2020Base obligation at award: $785,160
- Latest action
- May 5, 2025 — Funding onlyModification P00005; obligation change -$4,250; funding only: changes obligations, not scope
- Latest substantive action
- Oct 22, 2024 — Supplemental agreement (within scope)Modification P00004
- Latest funding action
- May 5, 2025 — Funding onlyModification P00005; obligation change -$4,250; funding only: changes obligations, not scope
- Actions by type
- Base award1
- Supplemental agreement (within scope)4
- Funding only1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- -$4,250
- Latest action: change in base and all options
- -$4,250
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
- Walsh-Healey Act (materials and supplies)
- Yes
Place and origin
- Domestic or foreign entity
- Other U.S. entity (e.g. government)B
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Delivery orderC
- Parent vehicle type
- IDCB
- Parent vehicle: multiple or single award
- Multiple awardM
- Parent vehicle agency
- National Institutes Of Health7529
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N910
- Transactions recorded under this award key
- 6
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N910
- Treasury accounts
- 075-2020/2020-0849-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression